Frankfurt - Delayed Quote EUR

ImmuCell Corporation (IUL.F)

4.6800 0.0000 (0.00%)
At close: 8:02 AM GMT+2
Loading Chart for IUL.F
DELL
  • Previous Close 4.6800
  • Open 4.6800
  • Bid 4.6400 x 300000
  • Ask 4.8200 x 300000
  • Day's Range 4.6800 - 4.6800
  • 52 Week Range 4.0600 - 5.4000
  • Volume 60
  • Avg. Volume 27
  • Market Cap (intraday) 36.688M
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7000
  • Earnings Date May 9, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

immucell.com

74

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IUL.F

Performance Overview: IUL.F

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

IUL.F
5.88%
S&P 500
4.14%

1-Year Return

IUL.F
7.83%
S&P 500
19.55%

3-Year Return

IUL.F
39.22%
S&P 500
18.68%

5-Year Return

IUL.F
11.25%
S&P 500
70.99%

Compare To: IUL.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IUL.F

Valuation Measures

As of 4/18/2024
  • Market Cap

    36.69M

  • Enterprise Value

    51.42M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.21

  • Price/Book (mrq)

    1.55

  • Enterprise Value/Revenue

    2.94

  • Enterprise Value/EBITDA

    -19.95

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -33.05%

  • Return on Assets (ttm)

    -7.36%

  • Return on Equity (ttm)

    -20.86%

  • Revenue (ttm)

    17.47M

  • Net Income Avi to Common (ttm)

    -5.77M

  • Diluted EPS (ttm)

    -0.7000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    978.74k

  • Total Debt/Equity (mrq)

    66.78%

  • Levered Free Cash Flow (ttm)

    -4.51M

Research Analysis: IUL.F

Analyst Price Targets

 

Earnings

Consensus EPS